Daraxonrasib Breakthrough in Pancreatic Cancer

A groundbreaking drug called daraxonrasib has nearly doubled survival for advanced pancreatic cancer patients, transforming outcomes from 6.7 to 13.2 months—a triumph after decades of stalled progress. Targeting the elusive RAS protein family, long considered “undruggable” due to its smooth surface, this breakthrough sparked standing ovations at major conferences and reignited hope for other stubborn cancers. Researchers are now exploring combinations and next-gen versions to tackle MYC, p53, and more, heralding a new era of precision oncology where even the most aggressive tumors may soon be conquerable. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/15de4c64724a283d